<strong>Background:</strong> <span style="font-family:Verdana;">Invasive breast cancer is the most common type of malignancy in women worldwide. Matrix Metalloproteinase</span><spa...<strong>Background:</strong> <span style="font-family:Verdana;">Invasive breast cancer is the most common type of malignancy in women worldwide. Matrix Metalloproteinase</span><span style="font-family:""><span style="font-family:Verdana;">-</span><span><span style="font-family:Verdana;">9 is a member of degrading enzymes required for tumor metastasis.</span><b><span style="font-family:Verdana;"> Aim: </span></b><span style="font-family:Verdana;">To assess the prognostic significance of the Matrix Metalloproteinase</span></span><span style="font-family:Verdana;">-</span><span><span style="font-family:Verdana;">9 expression in invasive breast cancer and its association with the clinicopathological features.</span><b><span style="font-family:Verdana;"> Patients and Methods: </span></b><span style="font-family:Verdana;">Cross-sectional study was conducted at the Oncology and Nuclear Therapy Unit, Suez Canal University Hospital. The study involved 33 females that were registered between January 1</span><sup><span style="font-family:Verdana;">st</span></sup><span style="font-family:Verdana;">, 2008 and December, 31</span><sup><span style="font-family:Verdana;">st</span></sup><span style="font-family:Verdana;">, 2012. The eligible participants had a confirmed non-metastatic invasive ductal carcinoma, underwent surgery that their paraffin blocks containing tumor were available. The participants’ tissue specimens were immune stained for Matrix Metalloproteinase</span></span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">9 expression level in the hospital pathology lab. Survival analysis and correlation models were conducted to explore the association between Matrix Metalloproteinase</span><span style="font-family:Verdana;">-</span><span><span style="font-family:Verdana;">9 expression level with clinicopathological parameters and survival.</span><b><span style="font-family:Verdana;"> Results</span></b><span style="font-family:Verdana;">: The mean age of participants was 51.2 ± 9.9 years. T展开更多
文摘<strong>Background:</strong> <span style="font-family:Verdana;">Invasive breast cancer is the most common type of malignancy in women worldwide. Matrix Metalloproteinase</span><span style="font-family:""><span style="font-family:Verdana;">-</span><span><span style="font-family:Verdana;">9 is a member of degrading enzymes required for tumor metastasis.</span><b><span style="font-family:Verdana;"> Aim: </span></b><span style="font-family:Verdana;">To assess the prognostic significance of the Matrix Metalloproteinase</span></span><span style="font-family:Verdana;">-</span><span><span style="font-family:Verdana;">9 expression in invasive breast cancer and its association with the clinicopathological features.</span><b><span style="font-family:Verdana;"> Patients and Methods: </span></b><span style="font-family:Verdana;">Cross-sectional study was conducted at the Oncology and Nuclear Therapy Unit, Suez Canal University Hospital. The study involved 33 females that were registered between January 1</span><sup><span style="font-family:Verdana;">st</span></sup><span style="font-family:Verdana;">, 2008 and December, 31</span><sup><span style="font-family:Verdana;">st</span></sup><span style="font-family:Verdana;">, 2012. The eligible participants had a confirmed non-metastatic invasive ductal carcinoma, underwent surgery that their paraffin blocks containing tumor were available. The participants’ tissue specimens were immune stained for Matrix Metalloproteinase</span></span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">9 expression level in the hospital pathology lab. Survival analysis and correlation models were conducted to explore the association between Matrix Metalloproteinase</span><span style="font-family:Verdana;">-</span><span><span style="font-family:Verdana;">9 expression level with clinicopathological parameters and survival.</span><b><span style="font-family:Verdana;"> Results</span></b><span style="font-family:Verdana;">: The mean age of participants was 51.2 ± 9.9 years. T
